Answers are grounded in this paper and cite their sources.
OBJECTIVE: To compare skin-related outcomes in women with vulvar lichen sclerosus treated with fractionated carbon dioxide laser with concomitant clobetasol propionate 0.05% with women treated with fractionated carbon dioxide laser plus placebo ointment. METHODS: This randomized, double-blind, placebo-controlled multicenter trial was conducted at nine U.S. sites from March 2022 to April 2025. English- or Spanish-speaking adult women with lichen sclerosus electing vulvar fractionated carbon dioxide laser treatment were eligible. Women were excluded if they had prior vaginal mesh prolapse repair, previous radiation therapy, prior laser, immunomodulators or systemic therapy for lichen sclerosus, active genital infection, suspicious vulvar lesion or malignancy, active treatment for malignancy, or poor wound healing or if they were currently pregnant, lactating, or planning pregnancy. All participants underwent three vulvar fractionated carbon dioxide laser treatments 4–6 weeks apart and were randomized 1:1 to concomitant clobetasol propionate 0.05% or petrolatum-based ointment (placebo) 0.25–0.5 g nightly for 4 weeks starting at first laser treatment and then twice weekly until end of study. The primary outcome was proportion of women with improvement of 16 or more points on the Skindex-29, a validated questionnaire measuring a patient's skin-related symptoms and functioning, assessed at 4–5 weeks after completion of fractionated carbon dioxide laser treatment. Additional outcomes included Skindex-29 domain scores, patient impression of improvement (PGI-I [Patient Global Impression of Improvement] score), treatment satisfaction, and adverse events. RESULTS: Two hundred one participants were randomized, and 180 (89 clobetasol vs 91 placebo) had complete data. Most women indicated symptom onset 1 year or more before lichen sclerosus diagnosis, and approximately 90% had previously used topical corticosteroids. Nearly a third of all participants achieved the primary outcome (30.3% clobetasol vs 27.5% placebo, P =.67). Participants in the clobetasol arm demonstrated a greater improvement in Skindex-29 symptom score (mean change −19.0±18.5 clobetasol vs −10.1±19.8 placebo, P <.01) and total score (mean change −13.0±15.9 clobetasol vs −8.1±15.5 placebo, P =.04). More participants were “satisfied” or “very satisfied” with treatment after clobetasol (85.4% clobetasol vs 69.2% placebo, P =.01). Fifteen adverse events occurred in 12 participants (6 per cohort). CONCLUSION: There was no difference in the proportion of patients improving at least 16 points on the Skindex-29 after combined vulvar fractionated carbon dioxide laser and clobetasol compared with placebo. The clobetasol group reported greater improvement in lichen sclerosus–specific symptoms and higher treatment satisfaction. The rates of adverse events were low regardless of concomitant therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04951206.
No takes yet. Share an insight, caveat, or question.
Dieter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: